U.S. markets closed
  • S&P 500

    4,152.10
    -36.33 (-0.87%)
     
  • Dow 30

    34,269.16
    -473.66 (-1.36%)
     
  • Nasdaq

    13,389.43
    -12.43 (-0.09%)
     
  • Russell 2000

    2,206.99
    -5.71 (-0.26%)
     
  • Crude Oil

    65.44
    +0.16 (+0.25%)
     
  • Gold

    1,837.70
    +1.60 (+0.09%)
     
  • Silver

    27.68
    +0.02 (+0.08%)
     
  • EUR/USD

    1.2151
    +0.0016 (+0.13%)
     
  • 10-Yr Bond

    1.6240
    +0.0220 (+1.37%)
     
  • GBP/USD

    1.4141
    +0.0020 (+0.14%)
     
  • USD/JPY

    108.6290
    -0.2120 (-0.19%)
     
  • BTC-USD

    56,467.83
    +589.68 (+1.06%)
     
  • CMC Crypto 200

    1,513.93
    +1,271.26 (+523.84%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Castle Biosciences, Inc. (CSTL) Moves 5.3% Higher: Will This Strength Last?

  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Castle Biosciences, Inc. (CSTL) shares ended the last trading session 5.3% higher at $65.42. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 36.2% loss over the past four weeks.

The stock price recovered after dipping a day before due to mixed fourth quarter earnings results.

Price and Consensus

Price Consensus Chart for Castle Biosciences, Inc.
Price Consensus Chart for Castle Biosciences, Inc.

This company is expected to post quarterly loss of $0.11 per share in its upcoming report, which represents a year-over-year change of -466.7%. Revenues are expected to be $16.64 million, down 4.5% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Castle Biosciences, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CSTL going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research